BEIGF:OTCMKTS
BeOne Medicines
US$ 21,95
0,00%
(0,00) 1D
9 jun, 12:49:46 GMT-4 · USD
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor BEIGF genereren…
Beursw.
42,40 mld.
Gem. vol.
0,00
Volume
0,00
52 wk hoog
US$ 24,92
52 wk laag
US$ 21,95
Bèta
0,84
Uitstaande aandelen
1,43 mld.
Aantal medewerkers
12K
Beursw.
42,40 mld.
Gem. vol.
0,00
Volume
0,00
52 wk hoog
US$ 24,92
52 wk laag
US$ 21,95
Bèta
0,84
Uitstaande aandelen
1,43 mld.
Aantal medewerkers
12K
Nieuwsartikelen
Van webbronnen en nieuwspartners
MarketBeat
·
2 dagen geleden
BeOne Medicines (NASDAQ:ONC) Stock Falls 5.8% - Here's What Happened
Profiel
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Over BeOne Medicines
CEOJohn Vincent Oyler | John Vincent Oyler
Medewerkers12K
Opgericht28 okt 2010
Hoofdkantoor-
Sector-
Websitebeonemedicines.com